Comparative Pharmacology
Head-to-head clinical analysis: TETRACHEL versus TETRACYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TETRACHEL versus TETRACYCLINE HYDROCHLORIDE.
TETRACHEL vs TETRACYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
250-500 mg orally every 6 hours; or 500 mg to 1 g intravenously every 12 hours. Maximum oral dose: 4 g/day.
None Documented
None Documented
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
6-11 hours (prolonged to 57-120 hours in severe renal impairment; reduced in hepatic dysfunction; clinically relevant for dosing interval adjustments).
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Renal (60% unchanged via glomerular filtration), biliary (40% as active drug and metabolites, with enterohepatic recirculation; fecal elimination of unabsorbed drug).
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic